Gastrin and gastrin receptor ligands - A review of recent patent literature

IDrugs

Volumn 5, Issue 7, 2002, Pages 689-695

  Steel, Katherine ^a  

^a James Black Foundation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYCLOHEXYLCARBONYLMETHYL 5 ETHYL 2,3 DIHYDRO 9 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [1 (3 AZABICYCLO[3.2.2]NONAN 3 YLCARBONYLMETHYL) 5 (2 FLUOROPHENYL) 2,3 DIHYDRO 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 2 OXO 1 PIVALOYLMETHYL 5 (2 PYRIDYL) 1H 1,4 BENZODIAZEPIN 3 YL] 3 [3 (METHYLAMINO)PHENYL]UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 6 [[(1 ADAMANTYLMETHYL)AMINO]CARBONYL] 5 [[1 [[(3,5 DICARBOXYPHENYL)AMINO]CARBONYL] 2 PHENYLETHYLAMINO]CARBONYL]INDOLE; AG 041R; ANTIBODY; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; GASTRAZOLE; GASTRIMMUNE; GASTRIN; GASTRIN ANTAGONIST; GASTRIN ANTIBODY; GASTRIN RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; INSULIN; JB 95008; LIGAND; N [1 (2 FLUOROPHENYL) 3,4,6,7 TETRAHYDRO 4 OXOPYRROLO[3,2,1 JK][1,4]BENZODIAZEPIN 3 YL] 1H INDOLE 2 CARBOXAMIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; RABEPRAZOLE; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; Z 360;

CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; ESOPHAGUS DISEASE; EXPERIMENTAL MODEL; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; HYPERPLASIA; NONHUMAN; PANCREATITIS; REVIEW; STOMACH ACID SECRETION; STOMACH LESION; STOMACH ULCER;

EID: 0141842721     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Friis-Hansen L: Lessons from the gastrin and gastrin receptor knockout mice. Scand J Clin Lab Invest (2001) 61(Suppl 234):41-46.
2. Dockray GJ, Varro A, Dimaline R, Wang T: The gastrins: Their production and biological activities. Annu Rev Physiol (2001) 63:119-139.
3. Dunlop J: CCK receptor antagonists. Gen Pharmacol (1998) 31(4):519-524.
4. Hakanson R, Ding XQ, Norlen P, Lindstrom E: CCK2 receptor antagonists: Pharmacological tools to study the gastrin-ECL cell-parietal cell axis. Regul Pept (1999) 80(1-2):1-12.
5. Jones R, Bytzer P: Review article: Acid suppression in the management of gastro-oesophageal reflux disease - An appraisal of treatment options in primary care. Aliment Pharmacol Ther (2001) 15(6):765-772.
6. Reubi JC, Schaer JC, Waser B: Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res (1997) 57(7):1377-1386. Describes extensive occurrence of gastrin receptors in human tumors.
7. 2 ligands with particularly detailed coverage of benzodiazepines.
8. Miura N, Yoneta T, Ukawa H, Fukuda Y, Eta R, Mera Y, Omata T, Kinomoto T, Kurimoto T, Itoh Z: Pharmacological profiles of Z-360, a novel CCKB/gastrin (CCK2) receptor antagonist with excellent oral potency. Gastroenterology (2001) 120(5 Suppl 1):A311.
9. Satoh Y, Tabuchi S, Mitsui H: Design of dual CCK-A and CCK-B receptor antagonists. Drugs Future (1997) 22(10):1117-1131.
10. Tabuchi S, Ito H, Sogabe H, Kuno M, Kinoshita T, Katumi I, Yamamoto N, Mitsui H, Satoh Y: Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419. Chem Pharm Bull (2000) 48(1):1-15.
11. Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S, Miyata K: (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benz o-diazepin-3-yl)-N′-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist. J Med Chem (1997) 40(3):331-341. Synthesis and properties of YF-476, which is probably the gastrin ligand with the optimum combination of potency and oral bioavailability to date.
12. Boyce M, Warrington S, Johnston A, Harris A: Effect on gastric pH of single doses of YF476, a new gastrin antagonist, compared with ranitidine and placebo. Br J Clin Pharmacol (2000) 49:493P-494P.
13. Boyce M, Warrington S, Johnston A, Harris A: Effect on gastric pH of repeated doses of YF476, a new gastrin antagonist, compared with omeprazole and placebo. Br J Clin Pharmacol (2000) 50(4):383P-384P. First report of tachyphylaxis with gastrin antagonists.
14. Boyce M, Warrington S, Lewis Y, Nentwich H, Harris A: Adaptation to the antisecretory effect of YF476, a new gastrin antagonist, in healthy men. Br J Clin Pharmacol (2002) 53(4):437P. Confirmation of tachyphylaxis with YF-476.
15. Schmitz F, Otte JM, Stechele HU, Reimann B, Banasiewicz T, Folsch UR, Schmidt WE, Herzig KH: CCK-B/gastrin receptors in human colorectal cancer. Eur J Clin Invest (2001) 31(9):812-820.
16. Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, Becker W: Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med (1999) 40(6):1029-1044.
17. Staley J, Jensen RT, Moody TW: CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells. Peptides (1990) 11(5):1033-1036.
18. Moody TW, Jensen RT: CI-988 inhibits growth of small cell lung cancer cells. J Pharmacol Exp Ther (2001) 299(3):1154-1160.
19. Waldum HL, Brenna E: Personal review: Is profound acid inhibition safe? Aliment Pharmacol Ther (2000) 14(1):15-22. This article questions the wisdom of long-term PPI therapy.
20. Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF: Closing the gastrin loop in pancreatic carcinoma: Coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer (2000) 88(11):2487-2494.
21. Dethloff LA, Barr BM, Bestervelt LL: Inhibition of gastrin-stimulated cell proliferation by the CCK-B/gastrin receptor ligand CI-988. Food Chem Toxicol (1999) 37(2-3):105-110.
22. Heneghan MA, Hull R, Kane P, Shankley N, Kalindjian S, Tredger JM, Black JW, Harrison PM: Use of a novel CCKB/gastrin receptor antagonist Gastrazole (JB5008) in patients with advanced pancreatic adenocarcinoma. Results of an open labeled pilot trial. Gastroenterology (2001) 120(5 Suppl 1):A612.
23. Chiba T, Kinoshita Y, Sawada M, Kishi K, Baba A, Hoshimo E: The role of endogenous gastrin in the development of enterochromaffin-like cell carcinoid tumors in Mastomys natalensis: A study with the specific gastrin receptor antagonist AG-041R. Yale J Biol Med (1998) 71(3-4):247-255.
24. Senior K: Immunisation blocks gastrin's ability to promote tumour cell division. Drug Disc Today (2001) 6(2):62-63. Brief article describing prospects for gastrimmune.
25. Aphton Corp: Aphton announces FDA grants Orphan-Drug Status for its anti-gastrin immunogen G17DT for treatment of pancreatic cancer. Press Release (2002) July 17.
26. Zeria Pharmaceutical Co Ltd (Shinozaki K, Yoneta T, Murata M, Miura N, Maeda K): 1,5-Benzodiazepine derivatives. WO-09825911 (1998).
27. Zeria Pharmaceutical Co Ltd (Shinozaki K, Yoneta T, Murata M, Miura N, Maeda K): 1,5-Benzodiazepine derivatives. WO-09964403 (1999).
28. Zeria Pharmaceutical Co Ltd (Shinozaki K, Murata M, Maeda K, Taguchi H, Kawase N, Miura N): Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same. WO-00140197 (2001).
29. Fujisawa Pharmaceutical Co Ltd/Nippon Shokubai Co Ltd (Satoh Y, Tabuchi S, Mitsui H, Katsumi I, Yamamoto N): 1,4-Benzodiazepinones and their uses as CCK antagonists. WO-09815535 (1998).
30. James Black Foundation Ltd (Kalindjian SB, Buck IM, Linney ID, Wright PT, Mc Donald IM, Steel KIM, Hull RAD, Roberts SP, Gaffen JD, Vinter JG, Walker MK, Black JW, Watt GF, Harper EA, Shankley NP, Tozer MJ, Dunstone DJ, Pether MJ, Lilley EJ, Sykes DA, Low CMRL, Griffin EP, Wright L): Gastrin and cholecystokinin receptor ligands. WO-00027823 (2000).
31. James Black Foundation Ltd (McDonald IM, Low CMR, Steel KIM, Spencer J): Pyrazole derivatives and their use as gastrin and cholecystokinin receptor ligands. WO-00190078 (200).
32. James Black Foundation Ltd (Linney ID, McDonald IM): Gastrin and cholecystokinin receptor ligands (IV). WO-00185704 (2001).
33. James Black Foundation Ltd (Kalindjian SB, Buck IM, Steel KIM, Wright PT, Tozer MJ, Pether MJ, Low CMR): Gastrin and cholecystokinin receptor ligands (II). WO-00185723 (2001).
34. James Black Foundation Ltd (Kalindjian SB, Buck IM, Low CMR, Tozer MJ): Gastrin and cholecystokinin receptor ligands (III). WO-00185724 (2001).
35. RTP Pharma Inc (Parikh I, Lane A, Nardi RV, Brand SJ): Treatment for diabetes. WO-00044400 (2000).
36. James Black Foundation Ltd (Kalindjian SB, Black JW, Hull RAD, Shankley NP, Mesens JL, Andries LJ): Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands. WO-00185167 (2001).
37. Chugai Pharmaceutical Co Ltd (Chiba T): Cancer cell proliferation inhibitors. WO-09802419 (1998).
38. Aphton Corporation (Gevas PC, Grimes S, Karr SL, Watson SA, Michaeli D): Combination therapy for the treatment of tumors. WO-09959628 (1999).
39. Aphton Corporation (Caplin M, Grimes S, Michaeli D, Watson SA): Immunogenic composition to the CCK-B/gastrin receptor and methods for the treatment of tumors. WO-09851337 (1998).
40. Aphton Corporation (Gevas PC, Grimes S, Karr S, Michaeli D): Method for the treatment of gastroesophageal reflux disease. WO-09959612 (1999).
41. Aphton Corporation (Gevas PC, Grimes S, Karr S, Michaeli D, Watson S): Prevention and treatment of hypergastrinemia. WO-09959631 (1999).